Clostridium difficile infection (CDI) is an increasingly recognised important healthcare-associated infection (HCAI). Fidaxomicin inhibits spore-formation and toxin production of C. difficile and has been associated with milder symptoms and a reduced risk of recurrence. This project will access the impact of clinical outcomes on patients who receive Fidaxomicin and identify recurring cases within the clinical environment.
